MPLT
MapLight TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MPLT
Maplight Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on central nervous system diseases
800 Chesapeake Drive
Redwood City
California 94063
--
MapLight Therapeutics, Inc., was incorporated under the laws of the State of Delaware in November 2018. The company is a clinical-stage biopharmaceutical company focused on improving the lives of patients with debilitating central nervous system (CNS) diseases. The company aims to address the lack of drug therapies for specific neural circuits in patients. Its discovery platform aims to identify neural circuits that are causally related to disease and target these neural circuits for therapeutic regulation. Its lead product candidate, ML-007C-MA, is a fixed-dose compound formulation designed to treat schizophrenia and psychosis caused by Alzheimer's disease, designed to activate specific muscarinic receptors in the central nervous system while minimizing peripheral side effects.
Company Financials
EPS
MPLT has released its 2025 Q3 earnings. EPS was reported at -37.18, versus the expected -1.73, missing expectations. The chart below visualizes how MPLT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
